Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: tAN for Opioid Relapse Prevention
NCT05053503Completed
- Sponsor
- Spark Biomedical
- Start
- May 2022
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial in opioid use disorder (OUD) and opioid withdrawal (6 arms), sponsored by Spark Biomedical. Primary endpoints: 14-Panel Urine Drug Screen and Self-Report of Drug Use. Started May 2022; status: completed.
02
Conditions
opioid use disorder (OUD)opioid withdrawal
Beyond the preview
Go deeper on NCT05053503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053503.